Publication date: 10 December 2026 Source: Molecular Therapy Advances, Volume 34, Issue 4 Author(s): Mehrafarin Ashiri, Emily N. Barker, Wenxuan Wang, Caleb Vegh, Andrew Hedman, Shou Liu, Lin Liu, Richard Hemming, Elaine Anjos, Shawn N. Whitehead, Brian L. Mark, Barbara Triggs-Raine
Evaluation of HexM and its high-level mannose 6-phosphorylated form, PhosHexM, as treatments of models of GM2 gangliosidoses. // Molecular Therapy Advances. – URL: https://www.sciencedirect.com/science/article/pii/S3117387X2600217X?dgcid=rss_sd_all
Evaluation of HexM and its high-level mannose 6-phosphorylated form, PhosHexM, as treatments of models of GM2 gangliosidoses. Molecular Therapy Advances. https://www.sciencedirect.com/science/article/pii/S3117387X2600217X?dgcid=rss_sd_all
“Evaluation of HexM and its high-level mannose 6-phosphorylated form, PhosHexM, as treatments of models of GM2 gangliosidoses.” Molecular Therapy Advances.
@article{article58977,
title = {Evaluation of HexM and its high-level mannose 6-phosphorylated form, PhosHexM, as treatments of models of GM2 gangliosidoses},
journal = {Molecular Therapy Advances},
url = {https://www.sciencedirect.com/science/article/pii/S3117387X2600217X?dgcid=rss_sd_all}
}